Fonseca Discuses Real-World Use of Daratumumab Across Lines of Therapy for Transplant-Ineligible Myeloma

Video

CancerNetwork® spoke with Rafael Fonseca, MD, about real-world use of daratumumab-containing regimens as either frontline or second-line therapy for transplant-ineligible multiple myeloma.

At the 63rd American Society of Hematology Annual Meeting & Exposition, CancerNetwork® sat down with Rafael Fonseca, MD, director of Innovation and Transformational Relationships at the Mayo Clinic in Phoenix, Arizona, to talk about an abstract that he presented on the use of daratumumab-containing regimens in patients with transplant-ineligible multiple myeloma. He said that standard practice regarding use of daratumumab in the front- or later-line settings may vary depending on the treatment facility.

Transcript:

In the United States, both the use of RVd [lenalidomide, bortezomib, and dexamethasone] as well as the MAIA trial [NCT02252172] regimen [daratumumab (Darzalex) plus lenalidomide and dexamethasone (D-Rd)] are accepted as standard of care. What I have perceived is that within the academic centers, more and more people are using the MAIA regimen. Part of this relates to the fact that the data for superiority are there, as well as a perceived superiority. That’s why we’re doing this modeling.

However, when one looks at the community practices, RVd still has a very strong hold on those prescribing patterns. This is probably related to the familiarity that our colleagues in the community have with a regimen like RVd, which has been used extensively. But over time, we’ve seen more and more patients being treated with a MAIA-type combination.

Reference

Fonesca R, Facon T, Hashim M, et al. First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios. Presented at the 2021 American Society of Hematology Annual Congress. December 11-14, 2021. Virtual. Abstract 118. https://bit.ly/3pLLttF

Recent Videos
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
Related Content